Capricorn Fund Managers Ltd Invests $4.12 Million in Pfizer Inc. $PFE

Capricorn Fund Managers Ltd bought a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 165,569 shares of the biopharmaceutical company’s stock, valued at approximately $4,123,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Y.D. More Investments Ltd raised its position in shares of Pfizer by 123.7% in the 4th quarter. Y.D. More Investments Ltd now owns 50,159 shares of the biopharmaceutical company’s stock valued at $1,249,000 after acquiring an additional 27,738 shares during the period. Capital Advisors Wealth Management LLC grew its holdings in Pfizer by 4.4% during the fourth quarter. Capital Advisors Wealth Management LLC now owns 10,833 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 452 shares during the period. Unison Advisors LLC increased its stake in Pfizer by 1.7% in the fourth quarter. Unison Advisors LLC now owns 95,314 shares of the biopharmaceutical company’s stock valued at $2,373,000 after purchasing an additional 1,631 shares in the last quarter. Leo Wealth LLC increased its stake in Pfizer by 25.4% in the fourth quarter. Leo Wealth LLC now owns 135,861 shares of the biopharmaceutical company’s stock valued at $3,383,000 after purchasing an additional 27,559 shares in the last quarter. Finally, MBA Advisors LLC raised its holdings in Pfizer by 10.9% in the fourth quarter. MBA Advisors LLC now owns 21,798 shares of the biopharmaceutical company’s stock worth $543,000 after purchasing an additional 2,151 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

NYSE:PFE opened at $28.37 on Monday. The stock has a 50-day simple moving average of $27.09 and a 200 day simple moving average of $25.84. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.75. The company has a market cap of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 EPS. The business’s revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Royal Bank Of Canada initiated coverage on Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. Barclays started coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.